ValuEngine cut shares of BioAmber Inc. (NYSE:BIOA) from a sell rating to a strong sell rating in a research report report published on Tuesday.

Several other research firms have also weighed in on BIOA. Zacks Investment Research lowered BioAmber from a hold rating to a sell rating in a research note on Monday, May 15th. Cowen and Company initiated coverage on BioAmber in a research note on Wednesday, April 12th. They set a market perform rating and a $2.50 price objective for the company.

Shares of BioAmber (BIOA) opened at 0.5335 on Tuesday. The stock’s market capitalization is $19.79 million. The stock has a 50 day moving average price of $2.22 and a 200 day moving average price of $2.62. BioAmber has a 12 month low of $0.52 and a 12 month high of $6.50.

BioAmber (NYSE:BIOA) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.03. The company had revenue of $4.12 million for the quarter, compared to the consensus estimate of $4.09 million. BioAmber had a negative return on equity of 56.55% and a negative net margin of 221.82%. On average, analysts anticipate that BioAmber will post ($0.48) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “BioAmber Inc. (BIOA) Downgraded by ValuEngine” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/08/11/bioamber-inc-bioa-downgraded-by-valuengine.html.

Several large investors have recently added to or reduced their stakes in the company. NN Investment Partners Holdings N.V. raised its stake in BioAmber by 160.7% in the second quarter. NN Investment Partners Holdings N.V. now owns 2,864,155 shares of the biotechnology company’s stock valued at $7,362,000 after buying an additional 1,765,579 shares in the last quarter. Sabby Management LLC bought a new stake in BioAmber during the first quarter valued at $3,388,000. FMR LLC raised its stake in BioAmber by 18.7% in the first quarter. FMR LLC now owns 1,335,000 shares of the biotechnology company’s stock valued at $3,097,000 after buying an additional 210,000 shares in the last quarter. Robecosam AG raised its stake in BioAmber by 3.1% in the first quarter. Robecosam AG now owns 825,000 shares of the biotechnology company’s stock valued at $1,898,000 after buying an additional 25,000 shares in the last quarter. Finally, TD Asset Management Inc. bought a new stake in BioAmber during the second quarter valued at $977,000. 46.96% of the stock is owned by institutional investors and hedge funds.

About BioAmber

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for BioAmber Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAmber Inc. and related stocks with our FREE daily email newsletter.